Ribera Healthcare Clinic
801 Encino Pl NE Suite D-7 · Albuquerque, NM 87102
3.5(48 Google reviews · 9 in past year)
ABQ Lipo Light · 3321 Candelaria Rd NE #130 · Albuquerque, NM 87107
5.0· 1 Google review
Listing updated October 2, 2026
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
The official website for ABQ Lipo Light in Albuquerque, NM did not load (ConnectionError: HTTPSConnectionPool(host='www.abqlipolight.com', port=443): Max retries exceeded with url: / (Caused by NameResolutionError("HTTPSConnection(host='www.abqlipolight.com', port=443): Failed to resolve 'www.abqlipolight.com' ([Errno -2] Name or service not known)"))), so this summary cannot be grounded in first-party page content. No medications, prices, or services are inferred from the directory dump.
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Not listed |
| Cash pay accepted | Yes |
| Accepts insurance — per practice website | — |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Counts computed by RetaMaps from public Google reviews; most recent review 2020-12-30. Read the reviews themselves on the practice's Google listing.
801 Encino Pl NE Suite D-7 · Albuquerque, NM 87102
3.5(48 Google reviews · 9 in past year)
3840 Commons Avenue Northeast · Albuquerque, NM 87109
5.0(31 Google reviews · 3 in past year)
10409 Montgomery Pkwy NE Ste 202G · Albuquerque, NM 87111
5.0(15 Google reviews)
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs